{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:20:53Z","timestamp":1793996453589,"version":"4.8.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971997"],"award-info":[{"award-number":["81971997"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The intricate etiology of autoimmune liver disease (AILD) involves genetic, environmental, and other factors that yet to be completely elucidated. This study comprehensively assessed the causal association between genetically predicted modifiable risk factors and AILD by employing Mendelian randomization.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Genetic variants associated with 29 exposure factors were obtained from genome-wide association studies (GWAS). Genetic association data with autoimmune hepatitis (AIH), primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) were also obtained from publicly available GWAS. Univariate and multivariate Mendelian randomization analyses were performed to identify potential risk factors for AILD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Genetically predicted rheumatoid arthritis (RA) (OR\u2009=\u20091.620, 95%CI 1.423\u20131.843, <jats:italic>P<\/jats:italic>\u2009=\u20092.506\u2009\u00d7\u200910<jats:sup>\u2212\u200913<\/jats:sup>) was significantly associated with an increased risk of AIH. Genetically predicted smoking initiation (OR\u2009=\u20091.637, 95%CI 1.055\u20132.540, <jats:italic>P<\/jats:italic>\u2009=\u20090.028), lower coffee intake (OR\u2009=\u20090.359, 95%CI 0.131\u20130.985, <jats:italic>P<\/jats:italic>\u2009=\u20090.047), cholelithiasis (OR\u2009=\u20091.134, 95%CI 1.023\u20131.257, <jats:italic>P<\/jats:italic>\u2009=\u20090.017) and higher C-reactive protein (CRP) (OR\u2009=\u20091.397, 95%CI 1.094\u20131.784, <jats:italic>P<\/jats:italic>\u2009=\u20090.007) were suggestively associated with an increased risk of AIH. Genetically predicted inflammatory bowel disease (IBD) (OR\u2009=\u20091.212, 95%CI 1.127\u20131.303, <jats:italic>P<\/jats:italic>\u2009=\u20092.015\u2009\u00d7\u200910<jats:sup>\u2212\u20097<\/jats:sup>) and RA (OR\u2009=\u20091.417, 95%CI 1.193\u20131.683, <jats:italic>P<\/jats:italic>\u2009=\u20097.193\u2009\u00d7\u200910<jats:sup>\u2212\u20095<\/jats:sup>) were significantly associated with increased risk of PBC. Genetically predicted smoking initiation (OR\u2009=\u20091.167, 95%CI 1.005\u20131.355, <jats:italic>P<\/jats:italic>\u2009=\u20090.043), systemic lupus erythematosus (SLE) (OR\u2009=\u20091.086, 95%CI 1.017\u20131.160, <jats:italic>P<\/jats:italic>\u2009=\u20090.014) and higher CRP (OR\u2009=\u20091.199, 95%CI 1.019\u20131.410, <jats:italic>P<\/jats:italic>\u2009=\u20090.028) were suggestively associated with an increased risk of PBC. Higher vitamin D<jats:sub>3<\/jats:sub> (OR\u2009=\u20090.741, 95%CI 0.560\u20130.980, <jats:italic>P<\/jats:italic>\u2009=\u20090.036) and calcium (OR\u2009=\u20090.834, 95%CI 0.699\u20130.995, <jats:italic>P<\/jats:italic>\u2009=\u20090.044) levels were suggestive protective factors for PBC. Genetically predicted smoking initiation (OR\u2009=\u20090.630, 95%CI 0.462\u20130.860, <jats:italic>P<\/jats:italic>\u2009=\u20090.004) was suggestively associated with a decreased risk of PSC. Genetically predicted IBD (OR\u2009=\u20091.252, 95%CI 1.164\u20131.346, <jats:italic>P<\/jats:italic>\u2009=\u20091.394\u2009\u00d7\u200910<jats:sup>\u2212\u20099<\/jats:sup>), RA (OR\u2009=\u20091.543, 95%CI 1.279\u20131.861, <jats:italic>P<\/jats:italic>\u2009=\u20095.728\u2009\u00d7\u200910<jats:sup>\u2212\u20096<\/jats:sup>) and lower glycosylated hemoglobin (HbA1c) (OR\u2009=\u20090.268, 95%CI 0.141\u20130.510, <jats:italic>P<\/jats:italic>\u2009=\u20096.172\u2009\u00d7\u200910<jats:sup>\u2212\u20095<\/jats:sup>) were positively associated with an increased risk of PSC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Evidence on the causal relationship between 29 genetically predicted modifiable risk factors and the risk of AIH, PBC, and PSC is provided by this study. These findings provide fresh perspectives on the management and prevention strategies for AILD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-024-05247-y","type":"journal-article","created":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T21:01:29Z","timestamp":1714856489000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Genetic association and causal relationship between multiple modifiable risk factors and autoimmune liver disease: a two-sample mendelian randomization study"],"prefix":"10.1186","volume":"22","author":[{"given":"Weize","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2826-7462","authenticated-orcid":false,"given":"Mingjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,4]]},"reference":[{"issue":"10","key":"5247_CR1","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1136\/gutjnl-2020-322362","volume":"70","author":"PJ Trivedi","year":"2021","unstructured":"Trivedi PJ, Hirschfield GM. Recent advances in clinical practice: epidemiology of autoimmune liver diseases. Gut. 2021;70(10):1989\u20132003. 10.1136. PubMed PMID: 34266966; PubMed Central PMCID: PMCQ1. \/gutjnl-2020-322362.","journal-title":"Gut"},{"key":"5247_CR2","doi-asserted-by":"publisher","unstructured":"Horst AK, Kumashie KG, Neumann K, Diehl L, Tiegs G. Antigen presentation, autoantibody production, and therapeutic targets in autoimmune liver disease. Cell Mol Immunol. 2021;18(1). https:\/\/doi.org\/10.1038\/s41423-020-00568-6. PubMed PMID: 33110250; PubMed Central PMCID: PMCQ1.","DOI":"10.1038\/s41423-020-00568-6"},{"issue":"3","key":"5247_CR3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S2468-1253","volume":"5","author":"RA Shah","year":"2020","unstructured":"Shah RA, Kowdley KV. Current and potential treatments for primary biliary cholangitis. Lancet Gastroenterol Hepatol. 2020;5(3):306\u201315. https:\/\/doi.org\/10.1016\/S2468-1253. (19)30343-7. PubMed PMID: 31806572; PubMed Central PMCID: PMCQ1.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"5247_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jaut.2018.10.020","volume":"95","author":"A Floreani","year":"2018","unstructured":"Floreani A, Restrepo-Jim\u00e9nez P, Secchi MF, De Martin S, Leung PSC, Krawitt E, et al. Etiopathogenesis of autoimmune hepatitis. J Autoimmun. 2018;95:133\u201343. https:\/\/doi.org\/10.1016\/j.jaut.2018.10.020. PubMed PMID: 30385083; PubMed Central PMCID: PMCQ1.","journal-title":"J Autoimmun"},{"key":"5247_CR5","doi-asserted-by":"publisher","unstructured":"Lamba M, Ngu JH, Stedman CAM. Trends in incidence of Autoimmune Liver diseases and increasing incidence of Autoimmune Hepatitis. Clin Gastroenterol Hepatol. 2021;19(3). https:\/\/doi.org\/10.1016\/j.cgh.2020.05.061. PubMed PMID: 32526342; PubMed Central PMCID: PMCQ1.","DOI":"10.1016\/j.cgh.2020.05.061"},{"issue":"10","key":"5247_CR6","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.14309\/ajg.0000000000000268","volume":"114","author":"RT Yokoda","year":"2019","unstructured":"Yokoda RT, Carey EJ. Primary biliary cholangitis and primary sclerosing Cholangitis. Am J Gastroenterol. 2019;114(10):1593\u2013605. https:\/\/doi.org\/10.14309\/ajg.0000000000000268. PubMed PMID: 31169523; PubMed Central PMCID: PMCQ1.","journal-title":"Am J Gastroenterol"},{"issue":"10266","key":"5247_CR7","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736","volume":"396","author":"A Lleo","year":"2020","unstructured":"Lleo A, Wang G-Q, Gershwin ME, Hirschfield GM. Primary biliary cholangitis. Lancet. 2020;396(10266):1915\u201326. https:\/\/doi.org\/10.1016\/S0140-6736. (20)31607-X. PubMed PMID: 33308474; PubMed Central PMCID: PMCQ1.","journal-title":"Lancet"},{"issue":"6","key":"5247_CR8","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1053\/j.gastro.2021.08.032","volume":"161","author":"B Barberio","year":"2021","unstructured":"Barberio B, Massimi D, Cazzagon N, Zingone F, Ford AC, Savarino EV. Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: a systematic review and Meta-analysis. Gastroenterology. 2021;161(6):1865\u201377. https:\/\/doi.org\/10.1053\/j.gastro.2021.08.032. PubMed PMID: 34425093; PubMed Central PMCID: PMCQ1.","journal-title":"Gastroenterology"},{"issue":"6","key":"5247_CR9","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s00535-020-01681-z","volume":"55","author":"M Vesterhus","year":"2020","unstructured":"Vesterhus M, Karlsen TH. Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities. J Gastroenterol. 2020;55(6):588\u2013614. https:\/\/doi.org\/10.1007\/s00535-020-01681-z. PubMed PMID: 32222826; PubMed Central PMCID: PMCQ1.","journal-title":"J Gastroenterol"},{"issue":"12","key":"5247_CR10","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1016\/j.cgh.2021.01.029","volume":"19","author":"GJ Webb","year":"2021","unstructured":"Webb GJ, Ryan RP, Marshall TP, Hirschfield GM. The epidemiology of UK Autoimmune Liver Disease varies with Geographic Latitude. Clin Gastroenterol Hepatol. 2021;19(12):2587\u201396. https:\/\/doi.org\/10.1016\/j.cgh.2021.01.029. PubMed PMID: 33493696; PubMed Central PMCID: PMCQ1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5247_CR11","doi-asserted-by":"crossref","unstructured":"Trivella J, John BV, Levy C. Primary biliary cholangitis: Epidemiology, prognosis, and treatment. Hepatol Commun. 2023;7(6). 10.1097\/. HC9.0000000000000179. PubMed PMID: 37267215; PubMed Central PMCID: PMCQ2.","DOI":"10.1097\/HC9.0000000000000179"},{"issue":"2","key":"5247_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s12016-020-08778-6","volume":"58","author":"S-P Liu","year":"2020","unstructured":"Liu S-P, Bian Z-H, Zhao Z-B, Wang J, Zhang W, Leung PSC, et al. Animal models of Autoimmune Liver diseases: a Comprehensive Review. Clin Rev Allergy Immunol. 2020;58(2):252\u201371. https:\/\/doi.org\/10.1007\/s12016-020-08778-6. PubMed PMID: 32076943; PubMed Central PMCID: PMCQ1.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"5247_CR13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.cld.2022.06","volume":"26","author":"AM Sy","year":"2022","unstructured":"Sy AM, Ferreira RD, John BV. Hepatocellular Carcinoma in primary biliary cholangitis. Clin Liver Dis. 2022;26(4):691\u2013704. https:\/\/doi.org\/10.1016\/j.cld.2022.06. .011. PubMed PMID: 36270724; PubMed Central PMCID: PMCQ2.","journal-title":"Clin Liver Dis"},{"issue":"4","key":"5247_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/13543784.2020.1733527","volume":"29","author":"C Chang","year":"2020","unstructured":"Chang C, Tanaka A, Bowlus C, Gershwin ME. The use of biologics in the treatment of autoimmune liver disease. Expert Opin Investig Drugs. 2020;29(4):385\u201398. PubMed PMID: 32102572; PubMed Central PMCID: PMCQ1.","journal-title":"Expert Opin Investig Drugs"},{"issue":"9","key":"5247_CR15","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","volume":"67","author":"GM Hirschfield","year":"2018","unstructured":"Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, H\u00fcbscher S, et al. The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018;67(9):1568\u201394. https:\/\/doi.org\/10.1136\/gutjnl-2017-315259. PubMed PMID: 29593060; PubMed Central PMCID: PMCQ1.","journal-title":"Gut"},{"issue":"4","key":"5247_CR16","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/hep.32117","volume":"75","author":"KD Lindor","year":"2022","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2021 practice guidance update from the American Association for the study of Liver diseases. Hepatology (Baltimore MD). 2022;75(4):1012\u20133. https:\/\/doi.org\/10.1002\/hep.32117. PubMed PMID: 34431119; PubMed Central PMCID: PMCQ1.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"23","key":"5247_CR17","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1056\/NEJMe1804945","volume":"378","author":"EJ Carey","year":"2018","unstructured":"Carey EJ. Progress in primary biliary cholangitis. N Engl J Med. 2018;378(23):2234\u20135. 10.1056\/. NEJMe1804945. PubMed PMID: 29874531; PubMed Central PMCID: PMCQ1.","journal-title":"N Engl J Med"},{"issue":"11\u201312","key":"5247_CR18","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1080\/17474124.2022.2153672","volume":"16","author":"L-X Huang","year":"2022","unstructured":"Huang L-X, Wang Z-L, Jin R, Chen H-S, Feng B. Incomplete response to ursodeoxycholic acid in primary biliary cholangitis: criteria, epidemiology, and possible mechanisms. Expert Rev Gastroenterol Hepatol. 2022;16(11\u201312):1065\u201378. PubMed PMID: 36469627; PubMed Central PMCID: PMCQ2.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"4","key":"5247_CR19","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1053\/j.gastro.2021.07.042","volume":"161","author":"G Rogler","year":"2021","unstructured":"Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal manifestations of Inflammatory Bowel Disease: current concepts, treatment, and implications for Disease Management. Gastroenterology. 2021;161(4):1118\u201332. https:\/\/doi.org\/10.1053\/j.gastro.2021.07.042. PubMed PMID: 34358489; PubMed Central PMCID: PMCQ1.","journal-title":"Gastroenterology"},{"key":"5247_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2018.10.014","volume":"59","author":"A Floreani","year":"2019","unstructured":"Floreani A, De Martin S, Secchi MF, Cazzagon N. Extrahepatic autoimmunity in autoimmune liver disease. Eur J Intern Med. 2019;59:1\u20137. https:\/\/doi.org\/10.1016\/j.ejim.2018.10.014. PubMed PMID: 30360943; PubMed Central PMCID: PMCQ1.","journal-title":"Eur J Intern Med"},{"key":"5247_CR21","doi-asserted-by":"crossref","unstructured":"Floreani A, Franceschet I, Cazzagon N. Primary biliary cirrhosis: overlaps with other autoimmune disorders. Semin Liver Dis. 2014;34(3):352\u2009\u2013\u200960. doi: 10.1055\/s-0034-1383734. PubMed PMID: 25057958; PubMed Central PMCID: PMCQ2.","DOI":"10.1055\/s-0034-1383734"},{"issue":"10","key":"5247_CR22","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1097\/MEG.0000000000000424","volume":"27","author":"P Muratori","year":"2015","unstructured":"Muratori P, Fabbri A, Lalanne C, Lenzi M, Muratori L. Autoimmune liver disease and concomitant extrahepatic autoimmune disease. Eur J Gastroenterol Hepatol. 2015;27(10):1175\u20139. 10.1097\/MEG.0000000000000424. PubMed PMID: 26148248; PubMed Central PMCID: PMCQ4.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"5247_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/joim.13644","volume":"294","author":"A Par\u00e9s","year":"2023","unstructured":"Par\u00e9s A, Gua\u00f1abens N. Bone fractures in primary biliary cholangitis. J Intern Med. 2023;294(2):159\u201360. https:\/\/doi.org\/10.1111\/joim.13644. PubMed PMID: 37165698; PubMed Central PMCID: PMCQ1.","journal-title":"J Intern Med"},{"issue":"2","key":"5247_CR24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/joim.13624","volume":"294","author":"J Sch\u00f6nau","year":"2023","unstructured":"Sch\u00f6nau J, Wester A, Schattenberg JM, Hagstr\u00f6m H. Risk of fractures and postfracture mortality in 3980 people with primary biliary cholangitis: a population-based cohort study. J Intern Med. 2023;294(2):164\u201377. https:\/\/doi.org\/10.1111\/joim.13624. PubMed PMID: 36823685; PubMed Central PMCID: PMCQ1.","journal-title":"J Intern Med"},{"issue":"31","key":"5247_CR25","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.3748\/wjg.v24.i31.3513","volume":"24","author":"CJ Danford","year":"2018","unstructured":"Danford CJ, Trivedi HD, Papamichael K, Tapper EB, Bonder A. Osteoporosis in primary biliary cholangitis. World J Gastroenterol. 2018;24(31):3513\u201320. https:\/\/doi.org\/10.3748\/wjg.v24.i31.3513. PubMed PMID: 30131657; PubMed Central PMCID: PMCQ2.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"5247_CR26","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1111\/jgh.13746","volume":"32","author":"A Seki","year":"2017","unstructured":"Seki A, Ikeda F, Miyatake H, Takaguchi K, Hayashi S, Osawa T, et al. Risk of secondary osteoporosis due to lobular cholestasis in non-cirrhotic primary biliary cholangitis. J Gastroenterol Hepatol. 2017;32(9):1611\u20136. https:\/\/doi.org\/10.1111\/jgh.13746. PubMed PMID: 28114749; PubMed Central PMCID: PMCQ2.","journal-title":"J Gastroenterol Hepatol"},{"key":"5247_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bpg.2018.06","volume":"34\u201335","author":"A Par\u00e9s","year":"2018","unstructured":"Par\u00e9s A, Gua\u00f1abens N. Primary biliary cholangitis and bone disease. Best Pract Res Clin Gastroenterol. 2018;34\u201335:63\u201370. https:\/\/doi.org\/10.1016\/j.bpg.2018.06. .005. PubMed PMID: 30343712; PubMed Central PMCID: PMCQ3.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"5","key":"5247_CR28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.clinre.2013.05.016","volume":"37","author":"DS Smyk","year":"2013","unstructured":"Smyk DS, Orfanidou T, Invernizzi P, Bogdanos DP, Lenzi M. Vitamin D in autoimmune liver disease. Clin Res Hepatol Gastroenterol. 2013;37(5):535\u201345. https:\/\/doi.org\/10.1016\/j.clinre.2013.05.016. PubMed PMID: 23845396; PubMed Central PMCID: PMCQ3.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"1","key":"5247_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1053\/jhep.2002.30084","volume":"35","author":"A Vogel","year":"2002","unstructured":"Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology (Baltimore MD). 2002;35(1):126\u201331. PubMed PMID: 11786968; PubMed Central PMCID: PMCQ1.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"11","key":"5247_CR30","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1080\/00365521.2020.1829030","volume":"55","author":"Z Wang","year":"2020","unstructured":"Wang Z, Peng C, Wang P, Sui J, Wang Y, Sun G, et al. Serum vitamin D level is related to disease progression in primary biliary cholangitis. Scand J Gastroenterol. 2020;55(11):1333\u201340. PubMed PMID: 33021858; PubMed Central PMCID: PMCQ4.","journal-title":"Scand J Gastroenterol"},{"key":"5247_CR31","doi-asserted-by":"publisher","first-page":"1055953","DOI":"10.3389\/fimmu.2022.1055953","volume":"13","author":"H Xu","year":"2022","unstructured":"Xu H, Wu Z, Feng F, Li Y, Zhang S. Low vitamin D concentrations and BMI are causal factors for primary biliary cholangitis: a mendelian randomization study. Front Immunol. 2022;13:1055953. https:\/\/doi.org\/10.3389\/fimmu.2022.1055953. PubMed PMID: 36605198; PubMed Central PMCID: PMCQ1.","journal-title":"Front Immunol"},{"key":"5247_CR32","doi-asserted-by":"publisher","unstructured":"Ebadi M, Ip S, Lytvyak E, Asghari S, Rider E, Mason A, et al. Vitamin D is Associated with Clinical outcomes in patients with primary biliary cholangitis. Nutrients. 2022;14(4). https:\/\/doi.org\/10.3390\/nu14040878. PubMed PMID: 35215528; PubMed Central PMCID: PMCQ1.","DOI":"10.3390\/nu14040878"},{"key":"5247_CR33","doi-asserted-by":"publisher","unstructured":"Kempinska-Podhorodecka A, Milkiewicz M, Wasik U, Ligocka J, Zawadzki M, Krawczyk M, et al. Decreased expression of vitamin D receptor affects an Immune response in primary biliary cholangitis via the VDR-miRNA155-SOCS1 pathway. Int J Mol Sci. 2017;18(2). https:\/\/doi.org\/10.3390\/ijms18020289. PubMed PMID: 28146070; PubMed Central PMCID: PMCQ1.","DOI":"10.3390\/ijms18020289"},{"key":"5247_CR34","doi-asserted-by":"publisher","unstructured":"Kempinska-Podhorodecka A, Adamowicz M, Chmielarz M, Janik MK, Milkiewicz P, Milkiewicz M. Vitamin-D receptor-gene polymorphisms affect quality of life in patients with Autoimmune Liver diseases. Nutrients. 2020;12(8). https:\/\/doi.org\/10.3390\/nu12082244. PubMed PMID: 32727130; PubMed Central PMCID: PMCQ1.","DOI":"10.3390\/nu12082244"},{"issue":"5","key":"5247_CR35","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1097\/HEP.0000000000000182","volume":"78","author":"L Gong","year":"2023","unstructured":"Gong L, Wei F, Gonzalez FJ, Li G. Hepatic fibrosis: targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines. Hepatology (Baltimore MD). 2023;78(5):1625\u201353. https:\/\/doi.org\/10.1097\/HEP.0000000000000182. PubMed PMID: 36626642; PubMed Central PMCID: PMCQ1.","journal-title":"Hepatology (Baltimore MD)"},{"key":"5247_CR36","doi-asserted-by":"publisher","unstructured":"Kempi\u0144ska-Podhorodecka A, Abramczyk J, Cielica E, Hu\u0142a B, Maciejowska H, Banales J, et al. Effect of low testosterone levels on the expression of Proliferator-activated receptor alpha in female patients with primary biliary cholangitis. Cells. 2023;12(18). https:\/\/doi.org\/10.3390\/cells12182273. PubMed PMID: 37759496; PubMed Central PMCID: PMCQ2.","DOI":"10.3390\/cells12182273"},{"issue":"8","key":"5247_CR37","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.dld.2023.02.020","volume":"55","author":"J Wu","year":"2023","unstructured":"Wu J, Fan X, Song Y. The causal effect of bioavailable testosterone on primary biliary cholangitis in female patients: a bidirectional mendelian randomization analysis. Dig Liver Dis. 2023;55(8):1091\u20137. https:\/\/doi.org\/10.1016\/j.dld.2023.02.020. PubMed PMID: 36922303; PubMed Central PMCID: PMCQ2.","journal-title":"Dig Liver Dis"},{"issue":"2","key":"5247_CR38","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00281-018-0715-8","volume":"41","author":"D Schwinge","year":"2019","unstructured":"Schwinge D, Schramm C. Sex-related factors in autoimmune liver diseases. Semin Immunopathol. 2019;41(2):165\u201375. https:\/\/doi.org\/10.1007\/s00281-018-0715-8. PubMed PMID: 30276446; PubMed Central PMCID: PMCQ1.","journal-title":"Semin Immunopathol"},{"issue":"11","key":"5247_CR39","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1681\/ASN.2016010098","volume":"27","author":"P Sekula","year":"2016","unstructured":"Sekula P, Del Greco MF, Pattaro C, K\u00f6ttgen A. Mendelian randomization as an Approach to assess causality using Observational Data. J Am Soc Nephrol. 2016;27(11):3253\u201365. PubMed PMID: 27486138; PubMed Central PMCID: PMCQ1.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"5247_CR40","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1093\/ije\/dyv071","volume":"44","author":"AGC Boef","year":"2015","unstructured":"Boef AGC, Dekkers OM, le Cessie S. Mendelian randomization studies: a review of the approaches used and the quality of reporting. Int J Epidemiol. 2015;44(2):496\u2013511. https:\/\/doi.org\/10.1093\/ije\/dyv071. PubMed PMID: 25953784; PubMed Central PMCID: PMCQ1.","journal-title":"Int J Epidemiol"},{"key":"5247_CR41","doi-asserted-by":"publisher","unstructured":"Birney E. Mendelian randomization. Cold Spring Harb Perspect Med. 2022;12(4). https:\/\/doi.org\/10.1101\/cshperspect.a041302. PubMed PMID: 34872952; PubMed Central PMCID: PMCQ2.","DOI":"10.1101\/cshperspect.a041302"},{"issue":"4","key":"5247_CR42","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/jrsm.1346","volume":"10","author":"J Bowden","year":"2019","unstructured":"Bowden J, Holmes MV. Meta-analysis and mendelian randomization: a review. Res Synth Methods. 2019;10(4):486\u201396. https:\/\/doi.org\/10.1002\/jrsm.1346. PubMed PMID: 30861319; PubMed Central PMCID: PMCQ1.","journal-title":"Res Synth Methods"},{"key":"5247_CR43","doi-asserted-by":"publisher","unstructured":"Sanderson E. Multivariable mendelian randomization and mediation. Cold Spring Harb Perspect Med. 2021;11(2). https:\/\/doi.org\/10.1101\/cshperspect.a038984. PubMed PMID: 32341063; PubMed Central PMCID: PMCQ2.","DOI":"10.1101\/cshperspect.a038984"},{"issue":"11","key":"5247_CR44","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/ng.3406","volume":"47","author":"B Bulik-Sullivan","year":"2015","unstructured":"Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh P-R, et al. An atlas of genetic correlations across human diseases and traits. Nat Genet. 2015;47(11):1236\u201341. https:\/\/doi.org\/10.1038\/ng.3406. PubMed PMID: 26414676; PubMed Central PMCID: PMCQ1.","journal-title":"Nat Genet"},{"issue":"3","key":"5247_CR45","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/ng.3211","volume":"47","author":"BK Bulik-Sullivan","year":"2015","unstructured":"Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Patterson N, et al. LD score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet. 2015;47(3):291\u20135. https:\/\/doi.org\/10.1038\/ng.3211. PubMed PMID: 25642630; PubMed Central PMCID: PMCQ1.","journal-title":"Nat Genet"},{"key":"5247_CR46","doi-asserted-by":"publisher","unstructured":"Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases. Cell Mol Immunol. 2021;18(1). https:\/\/doi.org\/10.1038\/s41423-020-00592-6. PubMed PMID: 33318628; PubMed Central PMCID: PMCQ1.","DOI":"10.1038\/s41423-020-00592-6"},{"issue":"5","key":"5247_CR47","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1002\/hep.23694","volume":"51","author":"CO Zein","year":"2010","unstructured":"Zein CO. Clearing the smoke in chronic liver diseases. Hepatology (Baltimore MD). 2010;51(5):1487\u201390. 10.1002. \/hep.23694. PubMed PMID: 20432251; PubMed Central PMCID: PMCQ1.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"5","key":"5247_CR48","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/hep.20907","volume":"42","author":"ME Gershwin","year":"2005","unstructured":"Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology (Baltimore MD). 2005;42(5):1194\u2013202. PubMed PMID: 16250040; PubMed Central PMCID: PMCQ1.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"1","key":"5247_CR49","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1053\/jhep.2001.21165","volume":"33","author":"A Parikh-Patel","year":"2001","unstructured":"Parikh-Patel A, Gold EB, Worman H, Krivy KE, Gershwin ME. Risk factors for primary biliary cirrhosis in a cohort of patients from the United States. Hepatology (Baltimore MD). 2001;33(1):16\u201321. PubMed PMID: 11124815; PubMed Central PMCID: PMCQ1.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"4","key":"5247_CR50","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/gut.2009.184218","volume":"59","author":"MI Prince","year":"2010","unstructured":"Prince MI, Ducker SJ, James OFW. Case-control studies of risk factors for primary biliary cirrhosis in two United Kingdom populations. Gut. 2010;59(4):508\u201312. doi: 10.1136\/gut.2009.184218. PubMed PMID: 20332522; PubMed Central PMCID: PMCQ1.","journal-title":"Gut"},{"issue":"5","key":"5247_CR51","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1053\/he.2000.7050","volume":"31","author":"D Howel","year":"2000","unstructured":"Howel D, Fischbacher CM, Bhopal RS, Gray J, Metcalf JV, James OF. An exploratory population-based case-control study of primary biliary cirrhosis. Hepatology (Baltimore MD). 2000;31(5):1055\u201360. PubMed PMID: 10796879; PubMed Central PMCID: PMCQ1.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"1","key":"5247_CR52","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jhep.2011.03.031","volume":"56","author":"C Corpechot","year":"2012","unstructured":"Corpechot C, Gaouar F, Chr\u00e9tien Y, Johanet C, Chazouill\u00e8res O, Poupon R. Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. J Hepatol. 2012;56(1):218\u201324. https:\/\/doi.org\/10.1016\/j.jhep.2011.03.031. PubMed PMID: 21703179; PubMed Central PMCID: PMCQ1.","journal-title":"J Hepatol"},{"issue":"6","key":"5247_CR53","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1080\/00365520902803515","volume":"44","author":"E Tsochatzis","year":"2009","unstructured":"Tsochatzis E, Papatheodoridis GV, Manolakopoulos S, Tiniakos DG, Manesis EK, Archimandritis AJ. Smoking is associated with steatosis and severe fibrosis in chronic hepatitis C but not B. Scand J Gastroenterol. 2009;44(6):752\u20139. PubMed PMID: 19296398; PubMed Central PMCID: PMCQ4.","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"5247_CR54","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1002\/hep.21423","volume":"44","author":"CO Zein","year":"2006","unstructured":"Zein CO, Beatty K, Post AB, Logan L, Debanne S, McCullough AJ. Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: a cross validated retrospective assessment. Hepatology (Baltimore MD). 2006;44(6):1564\u201371. PubMed PMID: 17133468; PubMed Central PMCID: PMCQ1.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"1","key":"5247_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.addbeh.2006.03.007","volume":"32","author":"CA Whetzel","year":"2007","unstructured":"Whetzel CA, Corwin EJ, Klein LC. Disruption in Th1\/Th2 immune response in young adult smokers. Addict Behav. 2007;32(1):1\u20138. PubMed PMID: 16644136; PubMed Central PMCID: PMCQ1.","journal-title":"Addict Behav"},{"issue":"3","key":"5247_CR56","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/hep.21076","volume":"43","author":"A Ala","year":"2006","unstructured":"Ala A, Stanca CM, Bu-Ghanim M, Ahmado I, Branch AD, Schiano TD, et al. Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology (Baltimore MD). 2006;43(3):525\u201331. PubMed PMID: 16496326; PubMed Central PMCID: PMCQ1.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"2","key":"5247_CR57","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.mehy.2014.12","volume":"84","author":"T Bose","year":"2015","unstructured":"Bose T. Bitter correlationship between autoimmune hepatitis and smoking. Med Hypotheses. 2015;84(2):118\u201321. https:\/\/doi.org\/10.1016\/j.mehy.2014.12. .006. PubMed PMID: 25543266; PubMed Central PMCID: PMCQ2.","journal-title":"Med Hypotheses"},{"issue":"1","key":"5247_CR58","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/liv.12894","volume":"36","author":"K Boonstra","year":"2016","unstructured":"Boonstra K, de Vries EMG, van Geloven N, van Erpecum KJ, Spanier M, Poen AC, et al. Risk factors for primary sclerosing cholangitis. Liver International: Official J Int Association Study Liver. 2016;36(1):84\u201391. PubMed PMID: 26077553; PubMed Central PMCID: PMCQ1.","journal-title":"Liver International: Official J Int Association Study Liver"},{"issue":"6","key":"5247_CR59","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1007\/s10620-021-06989-1","volume":"67","author":"C Lammert","year":"2022","unstructured":"Lammert C, Chalasani SN, Green K, Atkinson E, McCauley B, Lazaridis KN. Patients with Autoimmune Hepatitis Report Lower Lifetime Coffee Consumption. Dig Dis Sci. 2022;67(6):2594\u20139. https:\/\/doi.org\/10.1007\/s10620-021-06989-1. PubMed PMID: 33939140; PubMed Central PMCID: PMCQ3.","journal-title":"Dig Dis Sci"},{"key":"5247_CR60","doi-asserted-by":"publisher","first-page":"103188","DOI":"10.1016\/j.jaut.2024.103188","volume":"145","author":"W Huang","year":"2024","unstructured":"Huang W, Jin T, Zheng W, Yin Q, Yan Q, Pan H, et al. Identifying the genetic association between systemic lupus erythematosus and the risk of autoimmune liver diseases. J Autoimmun. 2024;145:103188. https:\/\/doi.org\/10.1016\/j.jaut.2024.103188. PubMed PMID: 38458076; PubMed Central PMCID: PMCQ1.","journal-title":"J Autoimmun"},{"issue":"8","key":"5247_CR61","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1177\/0961203320923398","volume":"29","author":"JA Gonz\u00e1lez-Regueiro","year":"2020","unstructured":"Gonz\u00e1lez-Regueiro JA, Cruz-Contreras M, Merayo-Chalico J, Barrera-Vargas A, Ruiz-Marg\u00e1in A, Campos-Murgu\u00eda A, et al. Hepatic manifestations in systemic lupus erythematosus. Lupus. 2020;29(8):813\u201324. doi: 10.1177\/0961203320923398. PubMed PMID: 32390496; PubMed Central PMCID: PMCQ3.","journal-title":"Lupus"},{"key":"5247_CR62","doi-asserted-by":"publisher","unstructured":"Heijke R, Ahmad A, Frodlund M, Wirestam L, Dahlstr\u00f6m \u00d6, Dahle C, et al. Usefulness of Clinical and Laboratory Criteria for diagnosing Autoimmune Liver Disease among patients with systemic Lupus Erythematosus: an observational study. J Clin Med. 2021;10(17). https:\/\/doi.org\/10.3390\/jcm10173820. PubMed PMID: 34501268; PubMed Central PMCID: PMCQ2.","DOI":"10.3390\/jcm10173820"},{"issue":"13","key":"5247_CR63","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.2169\/internalmedicine.52.9458","volume":"52","author":"A Takahashi","year":"2013","unstructured":"Takahashi A, Abe K, Saito R, Iwadate H, Okai K, Katsushima F, et al. Liver dysfunction in patients with systemic lupus erythematosus. Intern Med. 2013;52(13):1461\u20135. PubMed PMID: 23812192; PubMed Central PMCID: PMCQ4.","journal-title":"Intern Med"},{"key":"5247_CR64","doi-asserted-by":"crossref","unstructured":"Radovanovi\u0107-Dini\u0107 B, Te\u0161i\u0107-Rajkovi\u0107 S, Zivkovic V, Grgov S. Clinical connection between rheumatoid arthritis and liver damage. Rheumatol Int. 2018;38(5):715\u2009\u2013\u200924. doi: 10.1007\/s00296-018-4021-5. PubMed PMID: 29627896; PubMed Central PMCID: PMCQ2.","DOI":"10.1007\/s00296-018-4021-5"},{"key":"5247_CR65","doi-asserted-by":"publisher","first-page":"152142","DOI":"10.1016\/j.semarthrit.2022.152142","volume":"58","author":"J Fan","year":"2023","unstructured":"Fan J, Jiang T, He D. Genetic link between rheumatoid arthritis and autoimmune liver diseases: a two-sample mendelian randomization study. Semin Arthritis Rheum. 2023;58:152142. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152142. PubMed PMID: 36446255; PubMed Central PMCID: PMCQ2.","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"5247_CR66","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1136\/ard.60.11.1046","volume":"60","author":"B Marasini","year":"2001","unstructured":"Marasini B, Gagetta M, Rossi V, Ferrari P. Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients. Ann Rheum Dis. 2001;60(11):1046\u20139. PubMed PMID: 11602476; PubMed Central PMCID: PMCQ1.","journal-title":"Ann Rheum Dis"},{"issue":"31","key":"5247_CR67","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.3748\/wjg.v19.i31.5131","volume":"19","author":"L Wang","year":"2013","unstructured":"Wang L, Zhang F-C, Chen H, Zhang X, Xu D, Li Y-Z, et al. Connective tissue diseases in primary biliary cirrhosis: a population-based cohort study. World J Gastroenterol. 2013;19(31):5131\u20137. https:\/\/doi.org\/10.3748\/wjg.v19.i31.5131. PubMed PMID: 23964148; PubMed Central PMCID: PMCQ2.","journal-title":"World J Gastroenterol"},{"issue":"2\u20133","key":"5247_CR68","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s12016-014-8427-x","volume":"48","author":"A Floreani","year":"2015","unstructured":"Floreani A, Franceschet I, Cazzagon N, Spinazz\u00e8 A, Buja A, Furlan P, et al. Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clin Rev Allergy Immunol. 2015;48(2\u20133):192\u20137. https:\/\/doi.org\/10.1007\/s12016-014-8427-x. PubMed PMID: 24809534; PubMed Central PMCID: PMCQ1.","journal-title":"Clin Rev Allergy Immunol"},{"key":"5247_CR69","doi-asserted-by":"publisher","first-page":"391567","DOI":"10.1155\/2012\/391567","volume":"2012","author":"DS Smyk","year":"2012","unstructured":"Smyk DS, Bogdanos DP, Mytilinaiou MG, Burroughs AK, Rigopoulou EI. Rheumatoid arthritis and primary biliary cirrhosis: cause, consequence, or coincidence? Arthritis. 2012;2012:391567. https:\/\/doi.org\/10.1155\/2012\/391567. PubMed PMID: 23150824.","journal-title":"Arthritis"},{"issue":"3","key":"5247_CR70","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/liv.13236","volume":"37","author":"G-W Wong","year":"2017","unstructured":"Wong G-W, Yeong T, Lawrence D, Yeoman AD, Verma S, Heneghan MA. Concurrent extrahepatic autoimmunity in autoimmune hepatitis: implications for diagnosis, clinical course and long-term outcomes. Liver International: Official J Int Association Study Liver. 2017;37(3):449\u201357. https:\/\/doi.org\/10.1111\/liv.13236. PubMed PMID: 27541063; PubMed Central PMCID: PMCQ1.","journal-title":"Liver International: Official J Int Association Study Liver"},{"key":"5247_CR71","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10608-8","author":"L Chen","year":"2023","unstructured":"Chen L, Zhao Y, Li M, Lv G. Proteome-wide mendelian randomization highlights AIF1 and HLA-DQA2 as targets for primary sclerosing cholangitis. Hepatol Int. 2023. https:\/\/doi.org\/10.1007\/s12072-023-10608-8. PubMed PMID: 37950809; PubMed Central PMCID: PMCQ1.","journal-title":"Hepatol Int"},{"issue":"3","key":"5247_CR72","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","volume":"10","author":"M Harbord","year":"2016","unstructured":"Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, et al. The first European evidence-based Consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10(3):239\u201354. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv213. PubMed PMID: 26614685; PubMed Central PMCID: PMCQ1.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"5247_CR73","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jhep.2023.09.031","volume":"80","author":"KN van Munster","year":"2024","unstructured":"van Munster KN, Bergquist A, Ponsioen CY. Inflammatory bowel disease and primary sclerosing cholangitis: one disease or two? J Hepatol. 2024;80(1):155\u201368. https:\/\/doi.org\/10.1016\/j.jhep.2023.09.031. PubMed PMID: 37940453; PubMed Central PMCID: PMCQ1.","journal-title":"J Hepatol"},{"issue":"7","key":"5247_CR74","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/s12276-023-01042-9","volume":"55","author":"YS Kim","year":"2023","unstructured":"Kim YS, Hurley EH, Park Y, Ko S. Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD): a condition exemplifying the crosstalk of the gut-liver axis. Exp Mol Med. 2023;55(7):1380\u20137. https:\/\/doi.org\/10.1038\/s12276-023-01042-9. PubMed PMID: 37464092; PubMed Central PMCID: PMCQ1.","journal-title":"Exp Mol Med"},{"issue":"8","key":"5247_CR75","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1111\/liv.15616","volume":"43","author":"H Zhang","year":"2023","unstructured":"Zhang H, Chen L, Fan Z, Lv G. The causal effects of inflammatory bowel disease on primary biliary cholangitis: a bidirectional two-sample mendelian randomization study. Liver International: Official J Int Association Study Liver. 2023;43(8):1741\u20138. https:\/\/doi.org\/10.1111\/liv.15616. PubMed PMID: 37283182; PubMed Central PMCID: PMCQ1.","journal-title":"Liver International: Official J Int Association Study Liver"},{"issue":"1","key":"5247_CR76","doi-asserted-by":"publisher","first-page":"10950","DOI":"10.1038\/s41598-023-35785-2","volume":"13","author":"J Zhao","year":"2023","unstructured":"Zhao J, Li K, Liao X, Zhao Q. Causal associations between inflammatory bowel disease and primary biliary cholangitis: a two-sample bidirectional mendelian randomization study. Sci Rep. 2023;13(1):10950. https:\/\/doi.org\/10.1038\/s41598-023-35785-2. PubMed PMID: 37414807; PubMed Central PMCID: PMCQ2.","journal-title":"Sci Rep"},{"issue":"6","key":"5247_CR77","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3109\/00365521.2011.558114","volume":"46","author":"C Efe","year":"2011","unstructured":"Efe C, Purnak T, Ozaslan E, Ozbalkan Z, Karaaslan Y, Altiparmak E, et al. Autoimmune liver disease in patients with systemic lupus erythematosus: a retrospective analysis of 147 cases. Scand J Gastroenterol. 2011;46(6):732\u20137. https:\/\/doi.org\/10.3109\/00365521.2011.558114. PubMed PMID: 21348808; PubMed Central PMCID: PMCQ4.","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"5247_CR78","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41588-020-0631-4","volume":"52","author":"J Morrison","year":"2020","unstructured":"Morrison J, Knoblauch N, Marcus JH, Stephens M, He X. Mendelian randomization accounting for correlated and uncorrelated pleiotropic effects using genome-wide summary statistics. Nat Genet. 2020;52(7):740\u20137. https:\/\/doi.org\/10.1038\/s41588-020-0631-4. PubMed PMID: 32451458; PubMed Central PMCID: PMCQ1.","journal-title":"Nat Genet"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05247-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-05247-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05247-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T21:01:41Z","timestamp":1714856501000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-05247-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,4]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5247"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-05247-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,4]]},"assertion":[{"value":"7 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"425"}}